Drug-Drug Interactions

Pain Relief
Dependable Product Profile
Pharmacokinetic Profile
Flexible Dosing
Opioid Conversions

Opana® ER does not require dose adjustment for CYP3A4
or 2C9-mediated drug-drug interactions1,*

It is also important to consider pharmacodynamic interactions when prescribing Opana® ER (see Important Safety Information)

Opana® ER should be started at 1/3 to 1/2 of the usual dose in patients who are concurrently receiving
other CNS depressants.

Effect of inhibitors on CYP450-metabolized opioids

Effect of inducers on CYP450-metabolized opioids

*At therapeutically relevant plasma concentrations in in vivo and in vitro studies.

References

  1. Opana® ER (Oxymorphone Hydrochloride) Extended-Release Tablets CII [Prescribing Information]. Endo Pharmaceuticals. Chadds Ford, PA; 2012.
  2. ULTRAM® ER [Prescribing Information]. PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Raritan, NJ; 2009.
  3. OxyContin® [Prescribing Information]. Purdue Pharma L.P. Stamford, CT; 2010.
  4. Goodman LS, Limbird LE, Milinoff PB, et al, eds. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw Hill; 1996.
  5. Hartshorn EA, Tatro DS. Principles of drug interactions. In: Tatro DS, ed. Drug Interaction Facts.
    5th ed. St Louis, MO: Facts and Comparisons; 1996:xix.
  6. Adams M, Pieniaszek HJ Jr, Gammaitoni AR, Ahdieh H. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol. 2005;45(3):337-345.